HS
HSCS.US HeartSciences Inc.
- Market cap
- USD 10.6M
- P/E
- -
- P/B
- 70.85x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jul 2026.
Is HSCS.US undervalued?
Graham numberThe Graham number of HeartSciences Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
HeartSciences Inc. fundamental analysis
No fundamental analysis for HeartSciences Inc. yet.
HeartSciences Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same tes…
Full company profileHeartSciences Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
HeartSciences Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 64.2K | 25.6K | 14.4K | 5.15K | 18.6K | 4.35K | 4.32K | 8.40K |
| Gross Profit | -46.1K | -18.7K | -20.1K | -24.6K | -82.6K | -125K | -129K | -133K |
| Operating Income | -3.82M | -2.57M | -4.71M | -6.11M | -6.31M | -8.35M | -8.41M | -11.8M |
| EBITDA | -3.74M | -2.29M | -4.43M | -5.98M | -6.16M | -8.22M | -8.28M | -11.6M |
| Net Income | -3.81M | -2.45M | -4.83M | -6.35M | -6.61M | -8.77M | -9.14M | -12.7M |
| EPS | -115 | -74 | -145 | -80 | -19 | -9.34 | -3.48 | -3.46 |
| Balance Sheet | ||||||||
| Total Assets | 1.96M | 1.93M | 2.09M | 3.29M | 9.50M | 4.22M | 5.26B | 3.74M |
| Total Liabilities | 1.64M | 3.84M | 8.15M | 3.06M | 2.19M | 4.02M | 5.04B | 5.77M |
| Shareholders' Equity | 316K | -1.91M | -6.06M | 231K | 7.32M | 205K | 226M | -2.03M |
| Cash & Short-term Investments | 497K | 723K | 918K | 1.66M | 5.81M | 1.10M | 1.66B | 29.9M |
| Total Debt | 943K | 3.08M | 6.16M | 1.57M | 1.04M | 2.99M | 3.94B | 4.00M |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.84M | -2.45M | -3.64M | -5.77M | -6.07M | -7.41M | -7.43M | -5.28M |
| Capital Expenditure | 11.4K | 712.00 | 1.93K | 18.3K | 125K | 30.2K | 44.5K | 1.12M |
| Free Cash Flow | -3.85M | -2.45M | -3.65M | -5.79M | -6.20M | -7.44M | -7.47M | -5.28M |
| Ratios | ||||||||
| ROE | -1,207.8% | - | - | -2,756.1% | -90.3% | -4,272.2% | -4.1% | - |
| ROA | -194.9% | -127.2% | -231.1% | -193.3% | -69.5% | -207.6% | -0.2% | -339.6% |
| Net Profit Margin | -5,938.0% | -9,577.3% | -33,592.6% | -123,384.3% | -35,511.9% | -201,499.5% | -211,666.5% | -151,064.0% |
| Debt to Equity | 2.99x | - | - | 6.79x | 0.14x | 14.55x | 17.46x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
HeartSciences Inc. dividends
HeartSciences Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 1:100 on May 17, 2024.
Who owns HeartSciences Inc.
- Insiders 19.98%
- Institutions 4.40%
- Public & others 75.61%
- Shares outstanding 4.97M
- Free float 3.39M
Top funds holding HSCS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 15.8K | 0.32% | -0.38% | Sep 2026 |
| Fidelity Series Total Market Index | 2.69K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.25K | 0.05% | 0.00% | Sep 2026 |
Top institutions holding HSCS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TFB Advisors LLC | 29.7K | 0.60% | 0.00% | Sep 2026 |
| Geode Capital Management, LLC | 23.0K | 0.46% | -20.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 18.0K | 0.36% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 17.2K | 0.35% | 0.00% | Jun 2026 |
| Tradition Wealth Management LLC | 16.8K | 0.34% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 14.5K | 0.29% | 0.00% | Jun 2026 |
| Citigroup Inc | 5.86K | 0.12% | 0.00% | Jun 2026 |
| UBS Group AG | 5.81K | 0.12% | -10.25% | Jun 2026 |
| Tower Research Capital LLC | 1.57K | 0.03% | -23.55% | Jun 2026 |
| BlackRock Inc | 750.00 | 0.02% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 700.00 | 0.01% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 650.00 | 0.01% | +1,200.00% | Jun 2026 |
| Allied Private Wealth LLC | 120.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Financial Management Professionals Inc | 2.00 | 0.00% | 0.00% | Jun 2026 |
| DRW Securities, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisory Services Network, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
HeartSciences Inc. company profile
- Company name
- HeartSciences Inc.
- Ticker
- HSCS.US
- Exchange
- USA Stocks
- Listed since
- Jun 15, 2022
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 14
- Fiscal year end
- April
- Address
- 550 Reserve Street, Southlake, TX, United States, 76092
- Phone
- 682 237 7781
- Website
- heartsciences.com
About HeartSciences Inc.
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
HeartSciences Inc. management
2- Mr. Andrew SimpsonCEO, President & Chairman of the Board of Directors · born 1969
- Ms. Danielle WatsonCFO & Treasurer · born 1982